NCT00206518View on ClinicalTrials.gov

Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

October 31, 2016

Study Completion Date

October 10, 2016

Conditions
Breast Cancer
Interventions
DRUG

Taxotere/Docetaxel

Taxotere

DRUG

Adriamycin/Cytoxan

Adriamycin/Cytoxan

DRUG

doxorubicin

AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.

Trial Locations (1)

77030

Baylor Breast Center, Houston

All Listed Sponsors
collaborator

Baylor College of Medicine

OTHER

lead

Mothaffar Rimawi

OTHER

NCT00206518 - Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients | Biotech Hunter | Biotech Hunter